These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1100310)

  • 1. Effects of ticlopidine, a new platelet aggregation inhibitor in man.
    Thebault JJ; Blatrix CE; Blanchard JF; Panak EA
    Clin Pharmacol Ther; 1975 Oct; 18(4):485-90. PubMed ID: 1100310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compared effects of three dose-levels of ticlopidine on platelet function in normal subjects.
    David JL; Monfort F; Herion F; Raskinet R
    Thromb Res; 1979 Jan; 14(1):35-49. PubMed ID: 425084
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of platelet aggregation by a new agent, Ticlopidine.
    Ashida SI; Abiko Y
    Thromb Haemost; 1979 Feb; 40(3):542-50. PubMed ID: 425067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of ticlopidine on platelet function in normal volunteers and in patients with platelet hyperaggregability in vitro.
    Knudsen JB; Gormsen J
    Thromb Res; 1979; 16(5-6):663-71. PubMed ID: 524316
    [No Abstract]   [Full Text] [Related]  

  • 5. Ticlopidine hydrochloride: relationship between dose, kinetics, plasma concentration and effect on platelet function.
    Picard-Fraire C
    Thromb Res Suppl; 1983; 4():119-28. PubMed ID: 6356462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology of flurbiprofen: a novel inhibitor of platelet aggregation.
    Thebault JJ; Lagrue G; Blatrix CE; Cheynier L; Cluzan R
    Curr Med Res Opin; 1977; 5(1):130-4. PubMed ID: 913117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dilazep on platelet aggregation.
    Nakajima K; Shirai K; Takimoto M; Satoh F; Aoki M
    Arzneimittelforschung; 1974 Nov; 24(11A Suppl):1899-901. PubMed ID: 4480271
    [No Abstract]   [Full Text] [Related]  

  • 8. Ticlopidine in China: comparative study on the effect of two dose levels on bleeding time and platelet function in healthy volunteers.
    Ruan C; Destelle G; Wang Z; Wan H; He Y; Cheng D; Li P; Duffas M
    Haemostasis; 1989; 19(2):94-9. PubMed ID: 2731781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical evaluation of platelet antagonists on the ex vivo inhibitory effects of platelet aggregation].
    Sakata T; Kobayashi K; Katayama Y; Takada T; Matsuyama T
    Rinsho Byori; 1991 Mar; 39(3):315-20. PubMed ID: 2051607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ticlopidine on human platelet responsiveness ex vivo: comparison with aspirin.
    Nunn B; Lindsay R
    Thromb Res; 1980 Jun; 18(6):807-813. PubMed ID: 7414564
    [No Abstract]   [Full Text] [Related]  

  • 11. Ticlopidine - an antiplatelet drug: effects in human volunteers.
    O'Brien JR; Etherington MD; Shuttleworth RD
    Thromb Res; 1978 Aug; 13(2):245-54. PubMed ID: 694843
    [No Abstract]   [Full Text] [Related]  

  • 12. Failure of methylhistidines to inhibit platelet aggregation at concentrations found in uremic plasma.
    Davis JW; Nininger RJ; Phillips PE
    Am J Clin Nutr; 1975 Aug; 28(8):930-3. PubMed ID: 1146754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Studies on inhibition of platelet aggregation by carbocromen (author's transl)].
    Resag K; Melzer G; Nitz RE
    Arzneimittelforschung; 1976 Feb; 26(2):209-13. PubMed ID: 947200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
    Jakubowski JA; Payne CD; Weerakkody GJ; Brandt JT; Farid NA; Li YG; Naganuma H; Lachno DR; Winters KJ
    J Cardiovasc Pharmacol; 2007 Mar; 49(3):167-73. PubMed ID: 17414229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 6-methyl-1,2,3,5-tetrahydroimidazo(2,1-b)quinazolin-2-one, a potent inhibitor of ADP-induced platelet aggregation.
    Beverung WN; Partyka RA
    J Med Chem; 1975 Feb; 18(2):224-5. PubMed ID: 1120996
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of ticlopidine on neutrophil chemotaxis in rats.
    Cohn M; Matzner Y; Eldor A
    Haemostasis; 1985; 15(2):114-8. PubMed ID: 4007635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ticlopidine activity on platelet function in patients with enhanced platelet aggregation. A short-term crossover study.
    Gensini GF; Favilla S; Breschi C; Abbate R; Costanzo G; Neri Serneri GG
    Haemostasis; 1983; 13(5):294-300. PubMed ID: 6228500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interactions of ticlopidine and aspirin in normal subjects.
    Thebault JJ; Blatrix CE; Blanchard JF; Panak EA
    J Int Med Res; 1977; 5(6):405-11. PubMed ID: 590598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of ticlopidine: relation between dose and time of administration to platelet inhibition.
    Kuzniar J; Splawinska B; Malinga K; Mazurek AP; Splawinski J
    Int J Clin Pharmacol Ther; 1996 Aug; 34(8):357-61. PubMed ID: 8864800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of SolCD39, a novel inhibitor of Platelet Aggregation, on Platelet Deposition and Aggregation after PTCA in a Porcine Model.
    Buergler JM; Maliszewski CR; Broekman MJ; Kaluza GL; Schulz DG; Marcus AJ; Raizner AE; Kleiman NS; Ali NM
    J Thromb Thrombolysis; 2005 Apr; 19(2):115-22. PubMed ID: 16052302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.